The most common gene mutations in de novo AML include NPM1 (27%), FLT3 (28%), DNMT3A (26%), and IDH1/IDH2 (20%) with roughly 7% being IDH1 and 13% being IDH2 (68, 69). This evidence concerns the gene FLT3 and acute myeloid leukemia.